Prokaryotic Recombinant Protein Market Overview
Prokaryotic recombinant proteins are proteins encrypted by a gene (recombinant DNA) and cloned in a prokaryotic system (E.coli). High specificity and low immunogenicity of prokaryotic recombinant proteins make them suitable candidate for chronic therapies and several autoimmune disorders.
Monoclonal antibodies form the largest segment of the recombinant protein market. According to the World Health Organization (WHO), chronic diseases (Diabetes, Cancers, Cardiovascular diseases and others), will become 7th leading cause of death worldwide by 2030. This will fuel the growth of prokaryotic recombinant protein market by virtue of their greater benefits and minimal side effects in treating chronic and autoimmune diseases.
Prokaryotic Recombinant Protein Market: Drivers and Restraints
The high specificity and low immunogenicity of prokaryotic recombinant proteins make them the choice of treatment in a variety of chronic diseases. Moreover, increasing prevalence and incidence of chronic diseases such as diabetes, cancers and other autoimmune disorders are also going to drive prokaryotic recombinant protein market.
Rising inclination towards the biologics will speed up the growth of prokaryotic recombinant protein market. However, the high cost of the prokaryotic recombinant proteins will restrain the growth of the market in the forecast period. Besides, rising demand for biosimilars will also restrict the growth of prokaryotic recombinant protein market globally.
Prokaryotic Recombinant Protein Market: Overview
Prokaryotic recombinant protein market is growing at a rapid pace owing to the huge investments in research and development. The major players in the prokaryotic recombination protein market are collaborating to build upon the research and commercialization expertise. For instance, in 2013, GVK Biosciences collaborated with US-based Endo Pharma for using its research expertise whereas Endo will distribute the former's products in the global market.
In another setting, Novasep partnered with GTP in 2016 for robust production of monoclonal antibodies and recombinant proteins.
With the rise in the prevalence of the chronic disease, monoclonal antibodies will contribute the largest revenue share for prokaryotic recombinant proteins. It is expected that the use of monoclonal antibodies will be extensively used in the treatment of diabetes, cardiac problems and cancers that will lead to the growth of the prokaryotic recombinant proteins market.
Prokaryotic Recombinant Protein Market: Regional Overview
North America will drive the Prokaryotic recombinant protein market due to technological advancement and world-class research institutes in the U.S. and Canada. High prevalence of chronic diseases along with the development of new products in this region will trigger the growth of prokaryotic recombinant protein market. After North America, Prokaryotic recombinant protein market is then followed by due to the rising ageing population.
The strong healthcare payer-provider structure will fuel the growth of prokaryotic recombinant protein market. Asia-Pacific is estimated to show significant growth for Prokaryotic recombinant protein market due to rising prevalence diabetic population in India and China. Africa, Latin America and Middle East regions are expected to show slower growth for Prokaryotic recombinant protein market due to lack of awareness among the people in this region.
Prokaryotic Recombinant Protein Market: Key Players
Examples of some of the market participants in Prokaryotic recombinant protein market identified across the value chain Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche AG, Prospec-Tany Technogene Ltd, Cusabio Technology LLC., Randox Laboratories Ltd, Batavia Biosciences, Geno Technology Inc., Kaneka and Eurogentec S.A., Abnova Corporation, Cayman Chemical Company., Geltor IndieBio, Bioclone Inc., and others.
The key players building upon their capabilities by collaborating with firms having core expertise. For instance, in 2019, Genscript Biotech collaborated with REMD Biotherapeutics to develop and commercialize several bispecific antibodies.
The research report on Prokaryotic recombinant protein market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on Prokaryotic recombinant protein market provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on Prokaryotic recombinant protein Market
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Report on Prokaryotic recombinant protein market includes regional analysis
- North America (U.S., Canada)
- Latin America (Mexico. Brazil, Argentina)
- Europe (Germany, Italy, France, U.K, Spain, , Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, ASEAN)
- Oceania (Australia, New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report on Prokaryotic recombinant protein market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Prokaryotic Recombinant Protein Market: Segmentation
The global Prokaryotic recombinant protein market is classified on the basis of product type, therapy area, application and end user.
Based on product type, Prokaryotic recombinant protein market is segmented into following:
- Growth factors
- Tumor Necrosis factors
- Blood clotting factors
- Thrombolytic drugs
Based on therapy area, Prokaryotic recombinant protein market is segmented into following:
- Myocardial Infarction
- Congestive Heart Failure
- Cerebral Apoplexy
- Crohn’s Disease
- Cancer Therapies
Based on application, Prokaryotic recombinant protein market is segmented into following:
- Aptamer Development
- Western Blotting
- Protein Interaction
- Protein Structure
- Cell Culture Experiments
- Antibody Profiling
- Improved Altered Functions
Based on end user, Prokaryotic recombinant protein market is segmented into following:
- Biotechnology Companies
- Research institutes
- Contract Research organizations
- Hospital Laboratories